Randomized controlled trial to compare the efficacy and safety of oral paricalcitol with oral calcitriol in dialysis patients with secondary hyperparathyroidism

Nephrology

Volumn 18, Issue 3, 2013, Pages 194-200

  Ong, Loke Meng ^a   Narayanan, Punithavathi ^a   Goh, Heong Keong ^a   Manocha, Anita Bhajan ^b   Ghazali, Ahmad ^c   Omar, Mahanim ^d   Mohamad, Sukeri ^e   Goh, Bak Leong ^f   Shah, Shahnaz ^g   Seman, Mohd Ramli ^h   Vaithilingam, Indralingam ⁱ   Ghazalli, Rozina ^a   Rahmat, Korina ^j   Shaariah, Wan ^k   Ching, Chen Hua ^l  

^a Penang Adventist Hospital   (Malaysia)

^b Seberang Jaya Hospital   (Malaysia)

^c HOSPITAL KUALA LUMPUR   (Malaysia)

^d UNIVERSITI TEKNOLOGI MARA   (Malaysia)

^e RP Zainab II Hospital   (Malaysia)

^f Serdang Hospital   (Malaysia)

^g TAR Hospital   (Malaysia)

^h TA Afzan Hospital   (Malaysia)

ⁱ Taiping Hospital   (Malaysia)

^j Hospital Melaka   (Malaysia)

^k Pediatric Department   (Malaysia)

^l HOSPITAL SULTANAH BAHIYAH   (Malaysia)

more..

Author keywords

clinical trials; dialysis; hyperparathyroidism; vitamin D

Indexed keywords

ALKALINE PHOSPHATASE; CALCITRIOL; CALCIUM; CALCIUM PHOSPHATE; PARATHYROID HORMONE; PARICALCITOL;

ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; CALCIUM BLOOD LEVEL; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DENGUE; DIALYSIS; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; HYPERCALCEMIA; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; PERITONITIS; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION; SECONDARY HYPERPARATHYROIDISM; SEPTICEMIA; TREATMENT DURATION;

ADMINISTRATION, ORAL; ADULT; ALKALINE PHOSPHATASE; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; CALCITRIOL; CALCIUM; CHI-SQUARE DISTRIBUTION; DOWN-REGULATION; ERGOCALCIFEROLS; FEMALE; HUMANS; HYPERPARATHYROIDISM, SECONDARY; KAPLAN-MEIER ESTIMATE; KIDNEY FAILURE, CHRONIC; MALAYSIA; MALE; MIDDLE AGED; PARATHYROID HORMONE; PHOSPHATES; RENAL DIALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84874492697     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/nep.12029     Document Type: Article

References (12)

1. Levin A, Bakris GL, Molitch M, et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: Results of the study to evaluate early kidney disease. Kidney Int. 2007; 71: 31-38.
2. Brickman AS, Coburn JW, Norman AW,. Action of 1,25- dihydroxycholecalciferol, a potent, kidney-produced metabolite of vitamin D, in uremic man. N. Engl. J. Med. 1972; 287: 891-895.
3. Slatopolsky E, Weerts C, Thielan J, Horst R, Harter H, Martin KJ,. Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients. J. Clin. Invest. 1984; 74: 2136-2143.
4. Brown AJ, Finch J, Slatopolsky E,. Differential effects of 19-nor-1,25-dihydroxyvitamin D(2) and 1,25-dihydroxyvitamin D(3) on intestinal calcium and phosphate transport. J. Lab. Clin. Med. 2002; 139: 279-284.
5. Sprague SM, Llach F, Amdahl M, Taccetta C, Batlle D,. Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int. 2003; 63: 1483-1490.
6. Ross EA, Tian J, Abboud H, et al. Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis. Am. J. Nephrol. 2008; 28: 97-106.
7. Sprague SM, Lerma E, McCormmick D, Abraham M, Batlle D,. Suppression of parathyroid hormone secretion in hemodialysis patients: Comparison of paricalcitol with calcitriol. Am. J. Kidney Dis. 2001; 28 (5 Suppl 5): S51-56.
8. Martin KJ, González EA, Gellens M, Hamm LL, Abboud H, Lindberg J,. 19-Nor-1-Alpha-25-dihydroxyvitamin D2 (Paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis. J. Am. Soc. Nephrol. 1998; 9: 1427-1432.
9. Llach F, Yudd M,. Paricalcitol in dialysis patients with calcitriol-resistant secondary hyperparathyroidism. Am. J. Kidney Dis. 2001; 38 (5 Suppl 5): S45-50.
10. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am. J. Kidney Dis. 2003; 42 (4 Suppl 3): S1-201.
11. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int. Suppl. 2009; 76 (113): S1-130.
12. Nakanishi S, Kazama JJ, Shigematsu T, et al. Comparison of intact PTH assay and whole PTH assay in long-term dialysis patients. Am. J. Kidney Dis. 2001; 38 (4 Suppl 1): S172-174.